Slide Left Slide Right

A UNIQUE FRENCH-GERMAN TRANSLATIONAL RESEARCH CENTER...

DISCOVER

...PUTTING THE PATIENT IN THE CENTER

Discover

DESIGNED TO ACCESS SCIENTIFIC EXCELLENCE IN EUROPE

DISCOVER

HIGHLY INNOVATIVE PATIENT BASED THERAPY DEVELOPMENT

Our focus is finding therapeutic solutions for patients with unmet medical needs. By developing cellular disease models directly from patient cells we develop therapeutic molecules up to the preclinical proof of concept, covering a
“from bed to bench and back to bed”

Learn more

ACCELERATING INNOVATION FOR PATIENTS



We are at a transformational time in biomedical research. Disruptive technologies have made human disease models a reality. Patient-derived material lies at the heart of this effort, which we at Ksilink access through our clinical programs. The models we are creating recapitulate the actual disease mechanisms in patients. Drug development, has been vertically accelerated as a result. Costs are lessened and chances of success bolstered. During this paradigm shift access to patient material and modeling know how is becoming a competitive game changer. Ksilink is designed to be at the forefront of this new development.

DISEASE AREAS AND NETWORK

DISEASE AREAS

Ksilink is working on diseases with a high medical need. By applying break-through technologies and know how we are combining medical needs with market expectations and technical feasability.






Ksilink’s network of excellence: Derisking Innovation

The complexity of patient based models is transforming entrenched work patterns between public research and industry. Access to patient derived, disease-relevant models and the most adequate competences for analyzing phenotypic screening results is becoming a competitive game changer. From an industry perspective, it is critical who will first access the relevant models – and further to that, who is able to best implement these models into the drug discovery process. Beside our in house expertise, Ksilink has access to a constantly growing network of leading clinicians and academics in France and Germany. Once the right partners are identified, Ksilink drives its collaborative drug discovery projects in a highly industrialized and standardized surrounding.  Ksilink thus offers a critical advantage to its clients– with its established expertise it can generate validated patient based models within a short time.














CONNECTING MEANINGFUL ENDPOINTS
Integrated Approach

TECHNOLOGIES

Derisking Drug Discovery

We view disease modeling 
as a competitive game changer in future drug development. iPSCs combined with the latest gene editing technologies can build highly relevant disease models that directly reflect human disease
 at a patient-specific level.
 The use of such models is likely 
to positively impact attrition during Phase II efficacy studies. Our strategy for competitiveness, therefore, expands well beyond libraries and Medchem. Combined with our high-end target free discovery platform and medicinal chemistry capacities, our approach is worldwide unique.

PARTNERING




MANAGING TEAM

Our talented team of professionals is acting with the commitment for being the most valuable partner for your drug discovery project. To learn more about our profiles please click on our team members.












FOUNDING PARTNERS

An integrated bed to bench to bed effort goes far beyond the capacities of a single player. It requires a concerted effort by many sectors of the biomedical enterprise in France and Germany. Ksilink can count on founding partners across a wide spectrum from both the private and public sectors. Together, Ksilink and its founding partners span the full range of development competences and effectively link patient needs to scientific excellence.

 

 

News

Ksilink, University of Bonn and Life & Brain

Read more

Mr Jean-Yves Le Déaut visits Ksilink

Read more

Ksilink and Anagenesis Biotechnologies

Read more

Mr Thierry Mandon visits Ksilink

Read more

Mrs Michèle Alliot-Marie visits Ksilink

Read more

Ksilink and Sanofi

Read more

Medicen

Read more

Ksilink, University of Bonn and Life & Brain

Read more

Mr Jean-Yves Le Déaut visits Ksilink

Read more

Ksilink and Anagenesis Biotechnologies

Read more

Mr Thierry Mandon visits Ksilink

Read more

Mrs Michèle Alliot-Marie visits Ksilink

Read more

Ksilink and Sanofi

Read more

Medicen

Read more

Ksilink will participate at Basellife and MipTec

Read more

European Business Development Conference

Read more

partnering of BIO Europe

Read more

BioFIT Strasbourg, France

Read more

Contact Us

Send Message

  • Our office address

    16 rue d’Ankara, 67000 Strasbourg, France

  • Write us at

    contact@ksilink.com

  • Visit us at

    www.ksilink.com

PSYCHIATRIC DISEASE

Psychiatric disorders are brain disorders of complex and variable genetic risk affecting over 15% of the population. The last decade has witnessed exciting and important advances in neuroscience of mental health including the mapping of neural circuitry and neurochemical mechanisms, identification of multiple genetic loci etc. Ksilink develops and validates valuable cellular iPSC based disease models from patients with psychiatric diseases such as schizophrenia for further target free drug discovery and development approaches.

MUSCLE DYSTROPHIES

Muscular Dystrophies are among the most common human genetic diseases. In general there is no cure for dystrophies and current treatments are limited to palliative care. The development of therapeutic treatments on the basis of a well characterized human iPSC based isogenic disease model is a real challenge and worldwide unique.

CARDIOVASCULAR DISEASES

Cardiomyopathies are a significant cause of heart failure and a leading indication for heart transplant among children and adults across the globe. Genetic inheritance with single gene mutations is found to affect a large group of patients with cardiomyopathies such as dilated cardiomyopathy or Catecholaminergic Polymorphic Ventricular Tachycardia. We develop new therapeutics against cardiomyopathies.

IMMUNOLOGY & CANCER

The communication between cancer and the immune system is a dynamic process, reminiscent of a balance. When immunity to cancer is ‘‘up’’ and the suppressive processes are ‘‘down,’’ cancer is under control. Sometimes this balance shifts and cancer appears. Ksilink is establishing complex but valuable cellular models to fight cancer by developing new therapeutics.

NEURODEGENERATION

The term ‘neurodegeneration’ involves a few diseases such as Alzheimer, Parkinson and Huntington’s disease affecting a constantly increasing population. The current market has no curative therapies and thus, available medications can only provide symptomatic relief. The market, hence, has a high potential for growth and should be tapped at the earliest. Ksilink can drive novel iPSC based disease model for subsequent drug discovery and development projects.

CO-FI-NANCEMENT

Ksilink's programs are subject to financial incentives. Public co-fi-nancement can account for up to 50% of development costs, decreasing the burden for clients, with no strings attached.

CO-INVESTMENT

Ksilink can engage as a program specific co-investor. Beyond public co-financement, Ksilink’s risk-shar-ing engagement can effectively reduce cash-in-hand needs for the client

INDUSTRIAL PROPERTY

Ksilink fosters innovation by assigning IP-rights to the client. In cases of risk-shar-ing engagement, fair compensation for Ksilink can be backloaded for Biotech and Academic clients

François Kien

Operations Manager

PhD in Virology from the University of Strasbourg. François spent 9 years in the International Network of Institut Pasteur as scientist and PR officer.

Antoine de Lacombe

Chief Financial Officer

Graduated from Université Paris-Dauphine in management and Institut d’Etudes Politiques de Paris in corporate finance. Antoine started with Ernst & Young Audit.  He then joined a privately-owned Investment fund where he gained experience in corporate finance and restructuring.

Yong-Jun Kwon

Head of Early Discovery and Technology Development

PhD in Functional Genomics from Yonsei University, Seoul, Korea.11 years of experience in translational research at the Institut Pasteur Korea and the Samsung Medical Center. He is responsible for Ksilink's high-content screening and technology development.

Ulf Nehrbass

Chief Executive Officer

A graduate of Cambridge University Ulf worked at the Rockefeller University, N.Y.C. and as Section Head of the Institut Pasteur, Paris, before moving into drug development as founder and CEO of Institut Pasteur Korea as well as QurlentTherapeutics.

Julia saulnier

Administrative Assistant

Julia joined Ksilink’s team in March 2017. She has a Master degree in International Trade and previously worked at SpanTech International SA, Belgium. Julia is now Personal Assistant to Ulf Nehrbass and Administrative Assistant for Ksilink.

Peter Sommer

R&D Portfolio Management and Competitive Intelligence

PhD in Virology from the University of the Saarland. Peter has gathered 15 years of experience in translational research in Pasteur Institutes in Europe and Asia.

Mona Boyé

Scouting and Bussiness Development 

Mona studied immunobiology in Constance, Germany and obtained her PhD degree in molecular biology from Cardiff Bioschool, UK. After her postdoc she absolved a training about Intellectual Property at the TH Berlin, Germany.

Mona Boyé

Scouting and Bussiness Development 

Mona studied immunobiology in Constance, Germany and obtained her PhD degree in molecular biology from Cardiff Bioschool, UK. After her postdoc she absolved a training about Intellectual Property at the TH Berlin, Germany.

Julia saulnier

Administrative Assistant

Julia joined Ksilink’s team in March 2017. She has a Master degree in International Trade and previously worked at SpanTech International SA, Belgium. Julia is now Personal Assistant to Ulf Nehrbass and Administrative Assistant for Ksilink.

Ulf Nehrbass

Chief Executive Officer

A graduate of Cambridge University Ulf worked at the Rockefeller University, N.Y.C. and as Section Head of the Institut Pasteur, Paris, before moving into drug development as founder and CEO of Institut Pasteur Korea as well as QurlentTherapeutics.

Antoine de Lacombe

Chief Financial Officer

Graduated from Université Paris-Dauphine in management and Institut d’Etudes Politiques de Paris in corporate finance. Antoine started with Ernst & Young Audit.  He then joined a privately-owned Investment fund where he gained experience in corporate finance and restructuring.

Peter Sommer

R&D Portfolio Management and Competitive Intelligence

PhD in Virology from the University of the Saarland. Peter has gathered 15 years of experience in translational research in Pasteur Institutes in Europe and Asia.

Yong-Jun Kwon

Head of Early Discovery and Technology Development

PhD in Functional Genomics from Yonsei University, Seoul, Korea.11 years of experience in translational research at the Institut Pasteur Korea and the Samsung Medical Center. He is responsible for Ksilink's high-content screening and technology development.